Boiron SA (BOI) AI Stock Analysis

6 Followers

Boiron SA

(Paris:BOI)

Select Model

Rating:67Neutral

Price Target:EUR 19.00▼(-0.26% Downside)

Action:reiterated

Date:09/24/26

The overall score reflects a financially solid company with strong margins, low debt, and consistently positive cash flows, but with uneven revenue and cash-flow trends that limit growth appeal. The valuation is a clear strength, with a low P/E and high dividend yield providing support for long-term investors. These positives are offset by very weak technicals, as the stock trades in a pronounced downtrend with oversold momentum, indicating elevated near-term downside risk despite the fundamentally attractive profile.

Positive Factors

Low LeverageVery low leverage gives Boiron substantial financial flexibility and reduces the burden of interest and refinancing costs. This conservative capital structure can help the company withstand operating volatility while preserving capacity to invest, maintain products, or return cash to shareholders.

Negative Factors

Severe Revenue ContractionThe severe reported 2025 revenue contraction and broader history of uneven declines weaken visibility into Boiron’s underlying demand. Persistent top-line instability can limit operating leverage, complicate planning, and make future earnings less dependable even when profitability improves.

Boiron SA (BOI) vs. iShares MSCI France ETF (EWQ)

Market Cap: EUR 338.56M
Dividend Yield: 7.09%
Average Volume (3M): 4,226
Price to Earnings (P/E): 12.8
Beta (1Y): 0.26
Revenue Growth: -1.80%
EPS Growth: 35.22%
Country: France
Employees: 2,623
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Boiron SA Business Overview & Revenue Model

Company Description

Boiron S.A. is a global pharmaceutical company specializing in the production and distribution of homeopathic remedies across France, Europe, North America, and other international markets. Its extensive product portfolio encompasses a range of non-p...

How the Company Makes Money

Boiron makes money primarily by selling its health products—most notably homeopathic medicines—through wholesale and retail distribution networks, with pharmacies as a key channel. Revenue is generated from the commercial sale of packaged remedies an...

Boiron SA Financial Statement Overview

Summary

Boiron combines high gross margins, solid profitability, and a very conservative balance sheet with choppy revenue growth and volatile but consistently positive cash flows, pointing to financial strength but limited growth visibility.

Income Statement

68Positive

Balance Sheet

78Positive

Cash Flow

63Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	495.78M	501.11M	487.56M	493.25M	534.24M	455.20M
Gross Profit	357.93M	365.73M	358.76M	358.08M	379.73M	327.62M
EBITDA	56.66M	66.30M	45.46M	73.67M	91.33M	78.75M
Net Income	26.19M	32.64M	11.34M	35.83M	44.67M	28.56M
Balance Sheet
Total Assets	568.69M	602.81M	576.33M	590.20M	789.49M	770.70M
Cash, Cash Equivalents and Short-Term Investments	50.67M	79.34M	64.71M	74.04M	250.94M	234.50M
Total Debt	23.80M	31.48M	14.97M	13.70M	22.17M	12.61M
Total Liabilities	193.25M	210.03M	198.15M	198.70M	232.15M	238.93M
Stockholders Equity	375.42M	392.76M	378.14M	393.66M	557.62M	531.74M
Cash Flow
Free Cash Flow	25.76M	29.72M	33.77M	27.47M	41.51M	13.46M
Operating Cash Flow	43.03M	53.24M	42.17M	45.49M	60.10M	33.88M
Investing Cash Flow	-25.27M	-23.39M	-18.36M	-22.93M	-15.28M	-11.92M
Financing Cash Flow	-29.86M	-24.39M	-27.85M	-198.41M	-28.99M	-22.00M

Boiron SA Technical Analysis

Technical Analysis SentimentNeutral

Last Price19.05

Price Trends

50DMA20.45Negative

100DMA23.67Negative

200DMA24.98Negative

Market Momentum

MACD-0.12Negative

RSI49.75Neutral

STOCH54.83Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BOI, the sentiment is Neutral. The current price of 19.05 is above the 20-day moving average (MA) of 18.67, below the 50-day MA of 20.45, and below the 200-day MA of 24.98, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 49.75 is Neutral, neither overbought nor oversold. The STOCH value of 54.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:BOI.

Boiron SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

FR:BOI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:IPN	71Outperform	EUR 13.84B	26.93	11.33%	0.96%	13.63%	14.45%
FR:BOI	67Neutral	EUR 337.23M	12.79	6.82%	7.09%	-1.80%	35.22%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
FR:VLA	47Neutral	EUR 509.31M	-2.92	-152.15%	―	-27.19%	-117.39%
FR:AB	45Neutral	EUR 59.85M	-8.47	27.28%	―	12.66%	44.01%
FR:DBV	40Underperform	EUR 670.78M	-3.91	-121.83%	―	―	45.11%

* General Sector Average

Performance Comparison

FR:BOI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
FR:BOI	Boiron SA	19.05	-5.68	-22.96%
FR:DBV	Dbv Technologies SA (UK)	2.12	-0.20	-8.62%
FR:IPN	Ipsen	167.00	36.78	28.25%
FR:ALCOX	Nicox SA	0.29	-0.04	-11.85%
FR:VLA	Valneva (0OB3)	2.63	-1.23	-31.92%
FR:AB	Ab Science	0.68	-0.47	-41.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 24, 2026

Boiron SA AI Stock Analysis